

Western Region Drugs Task Force Company Limited By Guarantee
(A company limited by guarantee, without a share capital)

Directors' Report and Financial Statements

for the year ended 31 December 2018

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

CONTENTS

	Page
Directors and Other Information	3
Directors' Report	4 - 5
Directors' Responsibilities Statement	6
Independent Auditor's Report	7 - 8
Appendix to the Independent Auditor's Report	9
Income and Expenditure Account	10
Balance Sheet	11
Reconciliation of Members' Funds	12
Cash Flow Statement	13
Notes to the Financial Statements	14 - 17
Supplementary Information on Trading Statement	19 - 21

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

DIRECTORS AND OTHER INFORMATION

Directors	Nuala Ford Richard O'Donovan Martin Lee (Resigned 27 March 2018) Deirdre Hurney (Resigned 31 August 2018)
Company Secretary	Nuala Ford
Company Number	460340
Registered Office	Unit 6 Galway Technology Park Parkmore Galway
Business Address	Unit 6 Galway Technology Park Parkmore Galway
Auditors	DFS & Co Audit Services Limited Chartered Accountants & Registered Auditors 2nd Floor Innovation House Ballybrit Business Park Ballybrit Galway
Bankers	Bank of Ireland Mervue Industrial Estate Galway
Solicitors	Sheehan & Co Solicitors Augustine Court St Augustine Street Galway

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

DIRECTORS' REPORT

for the year ended 31 December 2018

The directors present their report and the audited financial statements for the year ended 31 December 2018.

Principal Activity and Review of the Business

The principal activity of the company is to develop and implement an integrated community, voluntary and statutory strategy to combat substance abuse in Galway, Mayo and Roscommon.

The Company is limited by guarantee not having a share capital.

There has been no significant change in these activities during the year ended 31 December 2018.

Financial Results

The surplus/(deficit) for the year after providing for depreciation amounted to €33,431 (2017 - €(1,509)).

At the end of the year, the company has assets of €113,680 (2017 - €65,664) and liabilities of €63,560 (2017 - €48,975). The net assets of the company have increased by €33,431.

Directors and Secretary

The directors who served throughout the year, except as noted, were as follows:

Nuala Ford
Richard O'Donovan
Martin Lee (Resigned 27 March 2018)
Deirdre Hurney (Resigned 31 August 2018)

The secretary who served throughout the year was Nuala Ford.

There were no changes in shareholdings between 31 December 2018 and the date of signing the financial statements.

In accordance with the Articles of Association, the directors retire by rotation and, being eligible, offer themselves for re-election.

Future Developments

The company will continue to seek funding from government bodies to carry out its charitable activities.

Post Balance Sheet Events

There have been no significant events affecting the company since the year-end.

Political Contributions

The company did not make any disclosable political donations in the current year.

Auditors

The auditors, DFS & Co Audit Services Limited, (Chartered Accountants & Registered Auditors) have indicated their willingness to continue in office in accordance with the provisions of section 383(2) of the Companies Act 2014.

Statement on Relevant Audit Information

So far as the directors are aware, there is no relevant audit information of which the statutory auditors are unaware. The directors have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and they have established that the statutory auditors are aware of that information.

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

DIRECTORS' REPORT

for the year ended 31 December 2018


Accounting Records

To ensure that adequate accounting records are kept in accordance with sections 281 to 285 of the Companies Act 2014, the directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the company's office at Unit 6 Galway Technology Park, Parkmore, Galway.

Signed on behalf of the board



Nuala Ford
Director



Richard O'Donovan
Director

12 March 2019

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

DIRECTORS' RESPONSIBILITIES STATEMENT

for the year ended 31 December 2018

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:


- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy and enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014 and enable the financial statements to be readily and properly audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board



Nuala Ford
Director



Richard O'Donovan
Director

12 March 2019

INDEPENDENT AUDITOR'S REPORT

to the Members of Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Western Region Drugs Task Force Company Limited By Guarantee ('the company') for the year ended 31 December 2018 which comprise the Income and Expenditure Account, the Balance Sheet, the Reconciliation of Members' Funds, the Cash Flow Statement and the related notes to the financial statements, including a summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2018 and of its surplus for the year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland"; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Emphasis of Matter

The Financial Statements have been prepared on the going concern basis of accounts preparation, the validity of which depends upon future funding being available on a continuous basis from government agencies. In forming our opinion on the Financial Statements, we have considered the adequacy of the disclosure made in Note 3 to the Financial Statements concerning the company's ability to continue as a going concern. While the company is dependent on financing from government agencies there is no indication that this funding will not be available in the coming year. These conditions along with the other matters explained in Note 3 to the Financial Statements, indicates the existence of a material uncertainty which may cast doubt about the company's ability to continue as a going concern. The Financial Statements do not include the adjustments that would result if the company was unable to continue as a going concern.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the Provisions Available for Audits of Small Entities, in the circumstances set out in note 4 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which ISAs (Ireland) require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

INDEPENDENT AUDITOR'S REPORT

to the Members of Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

Opinions on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- in our opinion, the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- in our opinion, the Directors' Report has been prepared in accordance with the Companies Act 2014.

We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited. The financial statements are in agreement with the accounting records.

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the Directors' Report. The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

Respective responsibilities

Responsibilities of directors for the financial statements

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to the going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operation, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is contained in the appendix to this report, located at page 9, which is to be read as an integral part of our report.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume any responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



Maria Doonan

for and on behalf of

DFS & CO AUDIT SERVICES LIMITED

Chartered Accountants & Registered Auditors

2nd Floor

Innovation House

Ballybrit Business Park

Ballybrit

Galway

12 March 2019

Western Region Drugs Task Force Company Limited By Guarantee

APPENDIX TO THE INDEPENDENT AUDITOR'S REPORT

Further information regarding the scope of our responsibilities as auditor

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

INCOME AND EXPENDITURE ACCOUNT


for the year ended 31 December 2018

	Notes	2018 €	2017 €
Income		274,445	203,785
Expenditure		(241,014)	(205,296)
Surplus/(deficit) before interest		33,431	(1,511)
Interest receivable and similar income		-	2
Surplus/(deficit) before tax		33,431	(1,509)
Tax on surplus/(deficit)	7	-	-
Surplus/(deficit) for the year		33,431	(1,509)
Total comprehensive income		33,431	(1,509)

Approved by the board on 12 March 2019 and signed on its behalf by:



Nuala Ford
Director



Richard O'Donovan
Director

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

BALANCE SHEET

as at 31 December 2018


	Notes	2018 €	2017 €
Fixed Assets			
Tangible assets	8	6,448	6,157
Current Assets			
Debtors	9	23,434	2
Cash and cash equivalents		83,798	59,505
		107,232	59,507
Creditors: Amounts falling due within one year	10	(63,560)	(48,975)
Net Current Assets		43,672	10,532
Total Assets less Current Liabilities		50,120	16,689
Reserves			
Income and expenditure account		50,120	16,689
Members' Funds		50,120	16,689

The financial statements have been prepared in accordance with the small companies' regime.

Approved by the board on 12 March 2019 and signed on its behalf by:



Nuala Ford
Director



Richard O'Donovan
Director

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

RECONCILIATION OF MEMBERS' FUNDS

as at 31 December 2018

	Retained surplus	Total
	€	€
At 1 January 2017	18,198	18,198
Deficit for the year	(1,509)	(1,509)
At 31 December 2017	16,689	16,689
Surplus for the year	33,431	33,431
At 31 December 2018	<u>50,120</u>	<u>50,120</u>

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

CASH FLOW STATEMENT

for the year ended 31 December 2018

	Notes	2018 €	2017 €
Cash flows from operating activities			
Surplus/(deficit) for the year		33,431	(1,509)
Adjustments for:			
Interest receivable and similar income		-	(2)
Depreciation		1,671	1,426
		<u>35,102</u>	<u>(85)</u>
Movements in working capital:			
Movement in debtors		(23,432)	-
Movement in creditors		14,585	13,563
		<u>26,255</u>	<u>13,478</u>
Cash flows from investing activities			
Interest received		-	2
Payments to acquire tangible fixed assets		(1,962)	(2,369)
		<u>(1,962)</u>	<u>(2,367)</u>
Net increase in cash and cash equivalents		24,293	11,111
Cash and cash equivalents at beginning of financial year		59,505	48,394
Cash and cash equivalents at end of financial year	14	83,798	59,505

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

NOTES TO THE FINANCIAL STATEMENTS

for the year ended 31 December 2018

1. GENERAL INFORMATION

Western Region Drugs Task Force Company Limited By Guarantee is a company limited by guarantee incorporated in the Republic of Ireland. Unit 6 Galway Technology Park, Parkmore, Galway, is the registered office and is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. ACCOUNTING POLICIES

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 December 2018 have been prepared on the going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102).

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

Income

Grants

Grant Income from government agencies and other sundry sources are included in the Financial Statements on the basis of the amounts received and receivable.

Income

Income consisting of donations and other funds generated by voluntary activity are included in the Financial Statements when received. Income from these sources have been included in the Financial Statements only when realised or when the ultimate cash realisation of which can be assessed with reasonable certainty.

Tangible fixed assets and depreciation

Tangible fixed assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible fixed assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	12.5% Straight Line
----------------------------------	---	---------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable income for the year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

NOTES TO THE FINANCIAL STATEMENTS

continued

for the year ended 31 December 2018

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Income and Expenditure Account.

3. GOING CONCERN

The Financial Statements have been prepared on the going concern basis of accounts preparation, the validity of which depends upon future funding being available on a continuous basis from government agencies. The Directors are taking all necessary steps to ensure the continuation of support from the company's funding agencies. The Directors are confident that the company will receive funding for the foreseeable future which will allow the company to continue to operate. This uncertainty could result in the company being unable to realise its assets and discharge its liabilities in the normal course of business.

4. PROVISIONS AVAILABLE FOR AUDITS OF SMALL ENTITIES

In common with many other businesses of our size and nature, we use our auditors to prepare and submit tax returns to the Revenue and to assist with the preparation of the financial statements.

5. OPERATING SURPLUS/(DEFICIT)	2018	2017
	€	€
Operating surplus/(deficit) is stated after charging:		
Depreciation of tangible fixed assets	1,671	1,426
	<u> </u>	<u> </u>

6. EMPLOYEES

The company did not have a payroll function in 2018. The average monthly number of employees for 2017 was as follows:

	2018	2017
	Number	Number
Operational	-	3
Jigsaw Staff	-	3
	<u> </u>	<u> </u>
	-	6
	<u> </u>	<u> </u>

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

NOTES TO THE FINANCIAL STATEMENTS

continued

for the year ended 31 December 2018

7. TAX ON SURPLUS/(DEFICIT)

	2018 €	2017 €
(a) Analysis of charge in the year		
Current tax:		
Corporation tax at 12.50% (2017 - 12.50%) (Note 7 (b))	-	-

(b) Factors affecting tax charge for the year

The tax assessed for the year differs from the standard rate of corporation tax in the Republic of Ireland 12.50% (2017 - 12.50%). The differences are explained below:

	2018 €	2017 €
Surplus/(deficit) before tax	33,431	(1,509)
Surplus/(deficit) before tax multiplied by the standard rate of corporation tax in the Republic of Ireland at 12.50% (2017 - 12.50%)	4,179	(189)
Effects of:		
Charitable Exemption	(4,179)	189
Total tax charge for the year (Note 7 (a))	-	-

No charge to tax arises due to the tax exemption available to charities in accordance with Section 207 Taxes Consolidation Act 1997 (CHY No. 18126).

8. TANGIBLE FIXED ASSETS

	Fixtures, fittings and equipment €	Total €
Cost		
At 1 January 2018	11,410	11,410
Additions	1,962	1,962
At 31 December 2018	13,372	13,372
Depreciation		
At 1 January 2018	5,253	5,253
Charge for the year	1,671	1,671
At 31 December 2018	6,924	6,924
Net book value		
At 31 December 2018	6,448	6,448
At 31 December 2017	6,157	6,157

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

NOTES TO THE FINANCIAL STATEMENTS

continued

for the year ended 31 December 2018

9. DEBTORS	2018	2017
	€	€
Taxation	2	2
Prepayments	23,432	-
	<u>23,434</u>	<u>2</u>
10. CREDITORS	2018	2017
Amounts falling due within one year	€	€
Accruals	3,690	3,690
Deferred Income	59,870	45,285
	<u>63,560</u>	<u>48,975</u>

Repayment Terms

Accruals do not attract interest and their terms vary depending on contracts in place. Other Creditors do not attract interest and are due for immediate payment. Deferred Income is repayable in the event that funding is not used for the purpose for which it was intended.

11. CAPITAL COMMITMENTS

The company had no material capital commitments at the year-ended 31 December 2018.

12. CONTINGENT LIABILITIES

The company is funded by the provision of grant aid from the Health Service Executive (HSE) & the National Lottery. These grants may become repayable in the whole or in part if the company does not adhere to terms and conditions set down in funding agreements.

13. POST-BALANCE SHEET EVENTS

There have been no significant events affecting the company since the year end.

14. CASH AND CASH EQUIVALENTS	2018	2017
	€	€
Cash and bank balances	47,345	26,384
Cash equivalents	36,453	33,121
	<u>83,798</u>	<u>59,505</u>

15. RESERVES

Reserves represent the accumulated surplus earned by the company since incorporation.

16. APPROVAL OF FINANCIAL STATEMENTS

The financial statements were approved and authorised for issue by the board of directors on 12 March 2019.

WESTERN REGION DRUGS TASK FORCE COMPANY LIMITED BY GUARANTEE

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION

RELATING TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2018

NOT COVERED BY THE REPORT OF THE AUDITORS

THE FOLLOWING PAGES DO NOT FORM PART OF THE AUDITED FINANCIAL STATEMENTS

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

TRADING STATEMENT

for the year ended 31 December 2018

	Schedule	2018 €	2017 €
Income			
HSE Funding		96,841	120,003
Hse Funding - Family Support Mayo		46,326	-
Pobal		-	3,956
Direct Jigsaw Funding		-	11,829
Tulsa Funding		17,417	23,000
MWRDTF		-	500
Foroige		-	3,100
National Family Support Network		200	-
National Addiction Training Program - Prime for Life		17,786	-
Department of Social Protection		3,603	5,000
HSE Healthy Cities Funding		-	14,100
HSE Jigsaw Funding		-	11,097
South West Mayo Development Company		7,984	-
Galway Roscommon Education Training Board		13,917	4,200
Galway Roscommon Education Training Board - Planet Youth		4,000	-
Galway City Council		8,250	3,000
Mayo County Council		3,483	-
Roscommon QCBI		39,905	4,000
CYPSC Health & Wellbeing		14,733	-
		<u>274,445</u>	<u>203,785</u>
Gross surplus Percentage		<u>100.0%</u>	<u>100.0%</u>
Overhead expenses	1	(241,014)	(205,296)
		<u>33,431</u>	<u>(1,511)</u>
Miscellaneous income	2	-	2
Net surplus/(deficit)		<u><u>33,431</u></u>	<u><u>(1,509)</u></u>

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

SCHEDULE 1 : OVERHEAD EXPENSES

for the year ended 31 December 2018

	2018	2017
	€	€
Administration Expenses		
Wages and salaries	-	46,847
Social welfare costs	-	5,023
Staff training	15,062	14,244
Rent & Services payable	17,286	16,624
Light and heat	4,003	3,022
Cleaning & Waste	1,961	2,571
Repairs and maintenance	2,958	3,260
Printing, postage and stationery	12,290	10,086
Printing, postage and stationery - Planet Youth	1,066	-
Family Support Handbook	-	2,726
General Advertising	111	4,486
Telephone	4,878	5,803
Computer costs	3,278	6,511
App Development	1,427	16,678
Training Ancillary Costs	15,373	25,672
Legal and professional	-	20,002
Accountancy	1,230	1,230
Bank charges	223	346
Jigsaw Bank Charges	-	30
Healthy Cities Bank Charges	-	31
General expenses	150	-
Global Survey	-	4,750
Conference Expenses	1,285	1,158
Prime for Life	17,888	-
Ballinrobe Family Resource Centre	47,564	-
Plant Youth	80,839	-
Awareness Week	8,011	-
Mindfulness & Well Being Training	-	9,292
National Lottery Small Grants	-	1,017
Auditor's remuneration	2,460	2,461
Depreciation of tangible fixed assets	1,671	1,426
	<u>241,014</u>	<u>205,296</u>

Western Region Drugs Task Force Company Limited By Guarantee

(A company limited by guarantee, without a share capital)

SUPPLEMENTARY INFORMATION RELATING TO THE FINANCIAL STATEMENTS

SCHEDULE 2 : MISCELLANEOUS INCOME

for the year ended 31 December 2018

	2018	2017
	€	€
Miscellaneous Income		
Bank Interest	-	2
	<u> </u>	<u> </u>